echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > China's first fourth-line targeted drug for advanced gastrointestinal stromal tumors approved

    China's first fourth-line targeted drug for advanced gastrointestinal stromal tumors approved

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network, April 9th.
    Recently, the National Medical Products Administration of China approved the listing application of Qingle (Repetinib) for the treatment of 3 or more kinase inhibitors including imatinib.
    Of adult patients with advanced gastrointestinal stromal tumor (GIST).
    This approval marks that Repetinib will become the first GIST fourth-line therapeutic drug approved to be marketed in Mainland China, filling the gap in the treatment of this disease in my country.
     
    GIST is a mesenchymal tumor of the gastrointestinal tract.
    The disease can occur in any part of the entire digestive tract.
    The stomach and small intestine are the most common, accounting for 1% to 3% of gastrointestinal malignancies.
    It is a rare tumor and occurs more frequently in people over 50 years of age.
     
    At present, surgical resection is an important means for early treatment of GIST, but nearly 50% of patients with complete tumor resection still have recurrence or metastasis after surgery.
    For these patients with unresectable, metastatic or recurring advanced GIST, molecular targeted therapy is the main clinical treatment, and the commonly used drugs include imatinib, sunitinib and regorafenib, which are the first and second lines of GIST, respectively And third-line treatments are unanimously recommended by domestic and foreign guidelines.
     
    "But GIST is a complex disease , in some patients after receiving a second and third tier targeted drug therapy, still secondary to new genetic mutations that cause resistance to produce original drugs.
    " Peking University Tumor Hospital vice president Lin Shen Emphasize that due to the lack of effective back-line drugs, patients have a huge unmet need for treatment.
    Repetinib's approval for the market provides a new treatment plan for domestic GIST patients, and further helps patients improve their prognosis and improve their quality of life.
      Medical Network, April 9th.
    Recently, the National Medical Products Administration of China approved the listing application of Qingle (Repetinib) for the treatment of 3 or more kinase inhibitors including imatinib.
    Of adult patients with advanced gastrointestinal stromal tumor (GIST).
    This approval marks that Repetinib will become the first GIST fourth-line therapeutic drug approved to be marketed in Mainland China, filling the gap in the treatment of this disease in my country.
     
      GIST is a mesenchymal tumor of the gastrointestinal tract.
    The disease can occur in any part of the entire digestive tract.
    The stomach and small intestine are the most common, accounting for 1% to 3% of gastrointestinal malignancies.
    It is a rare tumor and occurs more frequently in people over 50 years of age.
     
      At present, surgical resection is an important means for early treatment of GIST, but nearly 50% of patients with complete tumor resection still have recurrence or metastasis after surgery.
    For these patients with unresectable, metastatic or recurring advanced GIST, molecular targeted therapy is the main clinical treatment, and the commonly used drugs include imatinib, sunitinib and regorafenib, which are the first and second lines of GIST, respectively And third-line treatments are unanimously recommended by domestic and foreign guidelines.
     
       "But GIST is a complex disease , in some patients after receiving a second and third tier targeted drug therapy, still secondary to new genetic mutations that cause resistance to produce original drugs.
    " Peking University Tumor Hospital vice president Lin Shen Emphasize that due to the lack of effective back-line drugs, patients have a huge unmet need for treatment.
    Repetinib's approval for the market provides a new treatment plan for domestic GIST patients, and further helps patients improve their prognosis and improve their quality of life.
      Medical Network, April 9th.
    Recently, the National Medical Products Administration of China approved the listing application of Qingle (Repetinib) for the treatment of 3 or more kinase inhibitors including imatinib.
    Of adult patients with advanced gastrointestinal stromal tumor (GIST).
    This approval marks that Repetinib will become the first GIST fourth-line therapeutic drug approved to be marketed in Mainland China, filling the gap in the treatment of this disease in my country.
     
      GIST is a mesenchymal tumor of the gastrointestinal tract.
    The disease can occur in any part of the entire digestive tract.
    The stomach and small intestine are the most common, accounting for 1% to 3% of gastrointestinal malignancies.
    It is a rare tumor and occurs more frequently in people over 50 years of age.
     
      At present, surgical resection is an important means for early treatment of GIST, but nearly 50% of patients with complete tumor resection still have recurrence or metastasis after surgery.
    For these patients with unresectable, metastatic or recurring advanced GIST, molecular targeted therapy is the main clinical treatment, and the commonly used drugs include imatinib, sunitinib and regorafenib, which are the first and second lines of GIST, respectively And third-line treatments are unanimously recommended by domestic and foreign guidelines.
     
       "But GIST is a complex disease , in some patients after receiving a second and third tier targeted drug therapy, still secondary to new genetic mutations that cause resistance to produce original drugs.
    " Peking University Tumor Hospital vice president Lin Shen Emphasize that due to the lack of effective back-line drugs, patients have a huge unmet need for treatment.
    Repetinib's approval for the market provides a new treatment plan for domestic GIST patients, and further helps patients improve their prognosis and improve their quality of life.
    Disease Disease Disease Tumor Hospital Tumor Tumor Hospital Hospital
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.